United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
United Therapeutics Price Performance
United Therapeutics stock traded down $1.05 during mid-day trading on Friday, reaching $306.97. The stock had a trading volume of 223,177 shares, compared to its average volume of 450,767. The company has a market capitalization of $13.79 billion, a price-to-earnings ratio of 13.48, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82. The company has a 50-day moving average price of $340.06 and a two-hundred day moving average price of $355.78.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the firm posted $4.36 earnings per share. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.
Institutional Trading of United Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics during the fourth quarter valued at $25,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the third quarter valued at $33,000. Dunhill Financial LLC lifted its holdings in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the period. State of Wyoming purchased a new position in United Therapeutics in the fourth quarter worth about $62,000. Finally, Millstone Evans Group LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $67,000. Institutional investors own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on UTHR. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.
Check Out Our Latest Stock Analysis on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
